Compare IBEX & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBEX | LXEO |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 448.0M | 396.5M |
| IPO Year | 2017 | 2023 |
| Metric | IBEX | LXEO |
|---|---|---|
| Price | $39.47 | $4.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $35.00 | $18.44 |
| AVG Volume (30 Days) | 93.7K | ★ 679.5K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.26 | ★ 39.81 |
| EPS | ★ 2.54 | N/A |
| Revenue | ★ $558,273,000.00 | $654,000.00 |
| Revenue This Year | $14.13 | N/A |
| Revenue Next Year | $5.68 | N/A |
| P/E Ratio | $14.58 | ★ N/A |
| Revenue Growth | ★ 9.77 | N/A |
| 52 Week Low | $25.94 | $3.99 |
| 52 Week High | $42.99 | $10.99 |
| Indicator | IBEX | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 52.35 | 39.07 |
| Support Level | $36.51 | $4.01 |
| Resistance Level | $39.81 | $5.38 |
| Average True Range (ATR) | 1.05 | 0.24 |
| MACD | -0.15 | -0.06 |
| Stochastic Oscillator | 32.99 | 5.59 |
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.